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Purpose: The treatments of nutraceuticals are currently used for
therapy in osteoarthritis. Clinical trials in human and veterinary
literature have documented the benefits of nutraceutical joint sup-
plements, such as glucosamine. However, there were not eluci-
dated significant histopathological and molecular changes in vivo
model. In this study, we investigated to evaluate the chondropro-
tective effects of glucosamine and/or mucopolysaccharide-pro-
tein comparing with treatment of COX-II inhibitor. Therefore we
observed degree of histopathological degradation and apoptosis
of articular cartilage in osteoarthritic rabbit model after adminis-
trations of glucosamine and/or mucopolysaccharide-protein.
Methods: Osteoarthritis was surgically induced in right knees
of rabbit by transecting the anterior cruciate ligament (ACLT).
Rabbits (six in each group) were received oral administration of
glucosamine-HCl (Glu) or mucopolysaccharide-protein (MucoP)
at a dose of 100 mg/kg, 6 times in a week. In the positive control
group, rabbits were treated COX-II inhibitor (celecoxib). Exper-
imental animals were examined by radiographs and sacrificed
at the 8th week of administration and removed the distal femora
for macroscopic and histological assessment. Apoptosis of chon-
drocytes were evaluated using TUNEL assay and immunohisto-
chemical expression of Caspase-3 in the cartilage area.
Results: In ACLT rabbits, there were not detected changes of
body weight due to administration of celecoxib, glucosamin-HCl
(Glu), or mucopolysaccharide-protein (MucoP) for 8 weeks. At
the 8-week after ACLT operation, radiographs of the right knees
varied from the lefts, but there were not significantly different be-
tween the groups. In gross morphology, critical osteoarthritic le-
sions, included fibrillation and irregularity of the cartilage surface,
were induced at the moderate and severe grade (as modifided
Mankin score). Histopathological quantitative evaluation of azan
stained sections in the medial femoral condyles were performed
and observed the severe loss of cartilage area and destruction
of tissue after ACLT. However, these gross and histopathological
lesions were significantly decreased in the rabbits of celecoxib
treatment. In particular, degenerative changes of cartilage and
cellularity of chondrocytes were reduced by oral treatment of Glu-
or MucoP- compared with those of non-treated rabbits. In MucoP-
treated rabbits, hypercellularity of chondrocytes was significantly
increased. In TUNEL assay of OA-induced rabbits, apoptosis of
chondrocytes frequently showed in surfaces of lateral and medial
femoral condyles. In the Glu- and celecoxib-treated groups, the
number of apoptotic chondrocytes was decreased. Moreover,
P309 – Table 1
Month 1 Month 3
Lumiracoxib dose Change relative to placebo 95% CI p Change relative to placebo 95% CI p
[mg/day] [mmHg] [mmHg]
Systolic BP
100 0.21 -0.75, 1.17 0.66 0.94 -0.32, 2.20 0.14
200 0.16 -0.68, 1.01 0.71 -0.32 -1.42, 0.79 0.57
400 0.37 -0.48, 1.23 0.39 0.16 -0.98, 1.31 0.78
Diastolic BP
100 0.16 -0.43, 0.75 0.59 0.46 -0.30, 1.22 0.24
200 0.03 -0.50, 0.56 0.91 -0.01 -0.69, 0.66 0.97
400 -0.11 -0.65, 0.42 0.68 -0.11 -0.81, 0.60 0.77
apoptosis of superficial zone was reduced in the cartilage of
MucoP-treated rabbits. In immunohistochemistry, the expression
of Caspase 3 was correlated with apoptotic changes between
groups.
Conclusions: In the ACLT rabbit model, osteoarthritis of ar-
ticular cartilage was significantly reduced by oral treatments
of glucosamin-HCl or mucopolysaccharide-protein for 8 weeks.
These data suggest that protective effects of nutraceuticals may
play a useful role in the clinical application. These effects could
be related to cartilage hypercellularity and reduction of apoptosis
due to treatment of glucosamine and/or mucopolysaccharide-
protein.
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Purpose: Hypertension is a leading co-morbidity in elderly arthri-
tis patients. Increases in systolic blood pressure (BP) of 1-5
mmHg have been shown to be associated with 7,100-35,700
additional ischemic heart disease and stroke events over 1 year
in a recent US study of osteoarthritis (OA) patients (Singh et
al. 2003). NSAIDs and COX-2 inhibitors have been shown to
increase BP, although there are differences among the individ-
ual drugs. Thus, chronic treatment of arthritis patients requires
selecting the most appropriate drug with a minimal impact on a
patient’s BP. In TARGET, lumiracoxib at a chronic dose of 400mg
od (four times the recommended dose for chronic osteoarthritis
used for up to one year) demonstrated a superior BP profile
than the comparator NSAIDs, ibuprofen 800mg tid and naproxen
500mg bid. To determine whether lumiracoxib increased blood
pressure compared to placebo-treated patients, we conducted a
meta-analysis of placebo-controlled trials including data of up to
3 months duration.
Methods: Office-visit, seated blood pressure measurement data
were available from 9,719 patients in 12 placebo-controlled trials
of up to 3 months duration. Change from baseline in diastolic and
systolic BP was examined for 6 different dose regimens of lumira-
coxib (50mg bid, 100mg od, 100mg bid, 200mg od, 200mg bid,
and 400mg od). Meta-analyses were conducted using individual
patient data from 9,611 patients providing BP measurements at
baseline and at least one post-baseline assessment. The effects
relative to placebo were evaluated at one and three months and
averaged across three months. Total daily doses of lumiracoxib
were used to investigate a dose-response relationship. The ef-
fects of baseline variables and prognostic factors on the relative
effect of lumiracoxib were also studied.
Results: Change from baseline for systolic and diastolic blood
pressure of lumiracoxib relative to placebo derived from a model
combining dose regimens (total daily dose) is shown in Table 1.
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None of the lumiracoxib regimens were significantly different
from placebo in terms of change from baseline for systolic or
diastolic blood pressure after 1 or 3 months. In addition, no dose-
response was observed. Adjustment for prognostic risk factors
(age, baseline systolic BP, history of hypertension, or prior use of
anti-hypertensive treatment) had no statistically significant effect
on the results.
Conclusions: This BP meta-analysis including data from 9,611
patients with arthritis demonstrated that lumiracoxib (100 - 400
mg once a day) had a BP profile (both systolic and diastolic)
comparable to patients receiving placebo.
Reference
[1] Singh et al., J Rheumatol, 2003;30:4
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Purpose: We found previously that hylan G-F 20, a cross-linked
high Mw hyaluronan, improved the cartilage structure in a rabbit
instability model of osteoarthritis (OA) at 1-week post treatment
regimen. In this study, we aimed to examine the sustainability
of the chondro-protective effect and the molecular mechanism
involved.
Methods: New Zealand White rabbits underwent either anterior
cruciate ligament transection (ACLT) or sham surgery. Four-
wk later, 3-weekly injections were performed in the operated
knee of 0.5 ml of hylan G-F 20 (8 mg/ml) or Lactated Ringer’s
Solution (LRS). Animals were sacrificed at 4-wk and 8-wk after
the last injection. Mankin scoring system was used to evaluate
the histological changes in cartilage. The cartilage structure
and the PG content were also examined separately using a
relative quantitative Carlson scoring system. The formation of
osteophytes was quantified by tracing the osteophyte area in
the trochlear ridge using MetaMorph image analysis of gross
morphological photos. RNA was isolated from cartilage and
synovium at 1-wk after the last injection and analyzed using
real-time PCR with rabbit specific primers.
Results: At 4-wk time point, the disease group (ACLT + LRS) de-
veloped severe OA, as shown by the significantly higher Mankin
score, Carlson cartilage score, and Carlson PG score than the
sham group (p<0.0001). There was no significant difference in
Mankin score and Carlson PG score between the OA groups
treated with or without hylan. However, hylan treated OA group
had a significant lower (better) Carlson cartilage structure score
(8.0 vs. 9.7; p = 0.0119; n = 10) and smaller osteophytes (1.42
x 107 vs. 3.58 x 107 pixels; p< 0.05) than the OA control. At
8-wk, the 3 scores of the OA control group were higher (worse)
than those at 4-wk; no significant difference was observed be-
tween hylan treated and non-treated OA groups. To explore the
mechanism of the chondro-protective effect of hylan G-F 20,
we examined the expression of several genes involved in carti-
lage matrix metabolism. The mRNA levels of type I (Col I) and
II collagen (Col II) were increased in OA cartilage compared
with sham control, which were further increased in hylan treated
OA cartilage. The ratio of Col II/Col I was lower in both non-
treated and treated OA cartilage than normal cartilage (control
= 199, OA = 25, and OA + hylan = 19), reflective of the de-
generative nature of OA. MMP13 was increased in OA cartilage
by >10-fold, and similar levels were detected in hylan-treated
cartilage. Significantly, MMP16 was identified as one of the
hylan-responsive genes that were altered in the OA cartilage
and synovium and were changed back toward normal in hylan
treated tissues. IL-1β mRNA levels were low or undetectable in
cartilage in control, OA, and OA + hylan. Low levels of IL-1β were
detected in the synovium, but the levels were unaltered across
the groups.
Conclusions: Three weekly IA injections with hylan G-F 20 im-
proved the integrity of cartilage structure, but not the PG content,
in a rabbit ACLT model of OA. This chondro-protective effect
was observed as early as 1-wk, sustained at 4-wk, and unde-
tectable at 8-wk post-treatment. Our findings of type II collagen
up-regulation and MMP16 down-regulation in hylan-treated joint
tissues suggest that hylan may protect the cartilage structure
by both stimulating the repair and inhibiting the degradation
processes at the molecular level. We also found that hylan treat-
ment reduced osteophyte formation in this rabbit model. Whether
these effects contribute to clinically reported long-term pain relief
associated with hylan G-F 20 requires further investigation. Anal-
yses of the genes that may contribute to OA pain are currently
underway.
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Purpose: An advanced WOMAC index - with two new subscales
as sport/recreation (SP) and quality of life (QL) - KOOS (Knee
Injury and Osteoarthritis Outcome Score) was recently proposed
also for population studies (EM Roos et al. 2006).
Aim: To investigate changes of KOOS in monitoring the sub-
jects with early knee osteoarthritis after different time intervals -
repeated measurements from one month on to 3 years.
Methods: Subjects were females selected from symptomatic
Elva cohort with early knee osteoarthritis. Their mean age was
45 years (35-54 yrs). Nine women passed the exercise therapy
(ExT) program with duration of 3 years (group I) when KOOS was
registrated monthly. Other 9, matched by sex, age and KOOS
basal values, formed the non-exercise therapy control (II) group.
All others (group III, n = 88), were tested before and after the 3
yrs period. KOOS has the following subscales Symptoms, Pain,
Activities of daily life, ADL, Sport and recreation, SP/Rec and
Quality of life, QL. Ten points in all KOOS subscales was taken
as clinically significant change. Besides the KOOS questionnaire
all subjects filled in standard VAS for pain and passed functional
tests for both knees. OA grade was diagnosed by radiographs:
axial for patello- and AP for tibiofemoral joint. At the baseline
radiographic grade I OA was found in 55% of cases, grade II in
9% and grade III in 2% of cases. For statistics the Mann-Whitney
test, the Spearman rank correlations, sign test and time series
analysis were used.
Results: In group I (ExT) and II (controls) registrated KOOS
subcsales no significant changes were observed at baseline.
Large individual fluctuations (up to +50/-50) were observed in
group I during the ExT. Also some relapses were observed
during the long period of ExT. Therefore, individual approach
is needed to use regular KOOS in ExT. The ExT reduced pain,
improved Sp/Rec and ADL, lesser extent - QL. The subgroup with
(IA) and without (IB) improvement of the quality of life (QL) was
find out.At the same time in the non-exercise therapy controls
significantly diminished SP/Rec and QL. After 3 years in the
group III significant changes were observed in two subscales:
more Symptoms (p < 0.05), more limitations in demanding knee
